In a prospective, single-center, randomized controlled trial with patients undergoing vascular groin surgery, Prevena Therapy aided in:
30-day post-operatively
11.9% (7/59) Prevena Therapy vs.
26.7% (16/60) SOC (p=0.001)*
30-day post-operatively
10.1% (6/59) Prevena Therapy vs.
21.6% (12/60) SOC (p=0.001)*
30-day post-operatively
6.8% (4/59) Prevena Therapy vs.
16.7% (10/60) SOC (p=0.04)*
Calculations are derived based on relative patient group incidence rate reported in this study.
*Statistically significant (p<0.05).
Implement PRM to help protect your high-risk patients. See the evidence behind the use of Prevena Therapy in vascular surgery.
Prevena Therapy is supported by more than 200 peer reviewed publications, with more being published every year. Download our easy to digest summary of the relevant clinical and health economic evidence to support the use of Prevena Therapy in vascular surgery.
Prevena Therapy can benefit all surgical patients—but choosing Prevena Therapy for your high-risk patients can lead to improved outcomes and significant cost savings. Our Proactive Risk Management (PRM) guides will help you to select the right patients, and the right procedures, helping you to optimise outcomes.
With over 200 peer reviewed publications studying Prevena Therapy, there is now sufficient evidence to provide evidence-based guidance to help support surgeon’s decision making.
Contact us to request a trial and consultation with a 3M clinical specialist
An error has occurred while submitting. Please try again later...
Your form was submitted successfully
NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals.